Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPEPPS | P55786 | 12/20 | 0.83 |
| ▸ | ANPEP | P15144 | 10/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.83 |
| ▸ | TP53 | P04637 | 2/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.83 |
| ▸ | LMNA | P02545 | 1/20 | 0.83 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.83 |
| ▸ | HTT | P42858 | 1/20 | 0.82 |
| ▸ | NPC1 | O15118 | 1/20 | 0.82 |
| ▸ | RAB9A | P51151 | 1/20 | 0.82 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.82 |
| ▸ | TRDMT1 | O14717 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Puromycin SCHEMBL6438088 | 0.94 | NPEPPS (0.74) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL14583945 | 0.91 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL21306559 | 0.91 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL21481061 | 0.91 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL3042415 | 0.91 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL24206459 | 0.91 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL20815730 | 0.91 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL22409382 | 0.91 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL22348910 | 0.91 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL20393806 | 0.91 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067031-B2 | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use | ANGIODEVICE INTERNATIONAL GMBH (CH) | 2011-11-29 | — | — | US | disclosed |
| US-20050281883-A1 | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use | ANGIODEVICE INTERNATIONAL GMBH (CH) | 2005-12-22 | — | — | US | disclosed |
| US-20050209664-A1 | Electrical devices and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-09-22 | — | — | US | disclosed |
| US-20050203635-A1 | Soft tissue implants and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-09-15 | — | — | US | disclosed |
| US-20050186246-A1 | Soft tissue implants and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-25 | — | — | US | disclosed |
| US-20050187639-A1 | Soft tissue implants and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-25 | — | — | US | disclosed |
| US-20050149157-A1 | Electrical devices and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-07-07 | — | — | US | disclosed |
| US-20050149158-A1 | Medical implants and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050281883-A1 | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use | ILK, FN1, MMP1 | NPEPPS 605/4885ANPEP 422/4885SMN1; SMN2 2232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.